BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
BRISTOL MYERS SQUIBB CO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$58.83−0.92 (-1.54%)
Close on Oct 19, 2026
- Market cap
- $120.48B
- P/E (TTM)
- 13.0
- Dividend yield
- 4.23%
Debt
Borrowings on the balance sheet, Jun 30, 2026
Total debt
$43.12B
$1.03B due within a year
Net debt
$34.40B
After $8.72B of cash
Implied interest rate
3.99%
FY2025 interest ÷ average debt
Interest coverage
–
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
Bond issues
Individual notes and bonds outstanding
Bond-level data is not connected yet
Coupon, maturity and amount of each note will come from the debt footnote in Bristol Myers Squibb's annual report. Trading prices and yields need FINRA TRACE data.